

Frequency, Spectrum, and Nonzero Fitness Costs of Resistance to Myxopyronin in *Staphylococcus aureus*

Aashish Srivastava, David Degen, Yon W. Ebright, and Richard H. Ebright

Howard Hughes Medical Institute, Waksman Institute, and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, New Jersey, USA

The antibiotic myxopyronin (Myx) functions by inhibiting bacterial RNA polymerase (RNAP). The binding site on RNAP for Myx—the RNAP “switch region SW1/SW2 subregion”—is different from the binding site on RNAP for the RNAP inhibitor currently used in broad-spectrum antibacterial therapy, rifampin (Rif). Here, we report the frequency, spectrum, and fitness costs of Myx resistance in *Staphylococcus aureus*. The resistance rate for Myx is 4×10^{-8} to 7×10^{-8} per generation, which is equal within error to the resistance rate for Rif (3×10^{-8} to 10×10^{-8} per generation). Substitutions conferring Myx resistance were obtained in the RNAP β subunit [six substitutions: V1080(1275)I, V1080(1275)L, E1084(1279)K, D1101(1296)E, S1127(1322)L, and S1127(1322)P] and the RNAP β' subunit [five substitutions: K334(345)N, T925(917)K, T925(917)R, G1172(1354)C, and G1172(1354)D] (residues numbered as in *Staphylococcus aureus* RNAP and, in parentheses, as in *Escherichia coli* RNAP). Sites of substitutions conferring Myx resistance map to the RNAP switch region SW1/SW2 subregion and do not overlap the binding site on RNAP for Rif, and, correspondingly, Myx-resistant mutants exhibit no cross-resistance to Rif. All substitutions conferring Myx resistance exhibit significant fitness costs (4 to 15% per generation). In contrast, at least three substitutions conferring Rif resistance exhibit no fitness costs ($\leq 0\%$ per generation). The observation that all Myx-resistant mutants have significant fitness costs whereas at least three Rif-resistant mutants have no fitness costs, together with the previously established inverse correlation between fitness cost and clinical prevalence, suggests that Myx resistance is likely to have lower clinical prevalence than Rif resistance.

Myxopyronin (Myx) is an α -pyrone antibiotic produced by *Mycrococcus fulvus* Mf50 (18, 20, 23, 49). Myx exhibits broad-spectrum antibacterial activity, with potent antibacterial activity against most Gram-positive species and some Gram-negative species. Myx is under investigation as a potential lead compound for broad-spectrum antibacterial therapy.

Myx functions by inhibiting bacterial RNA polymerase (RNAP) (3, 18, 20, 32, 49). The binding site on RNAP for Myx is located in the RNAP “switch region” and comprises the RNAP switch region structural elements termed “switch 1” and “switch 2,” (switch region SW1/SW2 subregion) (3, 18, 32, 49). The binding site on RNAP for Myx is different from the binding site on RNAP for the RNAP inhibitor in current use in broad-spectrum antibacterial therapy, rifampin (Rif) (3, 18, 32, 49). Accordingly, Myx exhibits no cross-resistance with Rif (18, 19, 32, 33, 49).

Previous studies have provided information about spontaneous resistance frequencies and resistance spectra for Myx (31, 32). However, the fitness costs of resistance have not previously been assessed.

In this work, we comprehensively evaluate the resistance properties of Myx in *Staphylococcus aureus*. We report (i) the spontaneous resistance rate for Myx in *S. aureus*, (ii) the spontaneous resistance spectrum of Myx in *S. aureus*, and (iii) the fitness costs of substitutions that confer Myx resistance.

MATERIALS AND METHODS

Materials. (\pm)-Myx B was synthesized as described in Hu et al. (19). Rif was purchased from Sigma, Inc. Bacterial strains were obtained from the American Type Culture Collection.

MICs. Minimal inhibitory concentrations (MICs) in column 2 of Table 1 were quantified using broth microdilution assays (8). MICs in column 3 of Table 1, and in Tables 3 and 4, were quantified using spiral gradient endpoint assays, essentially as described previously (38, 45, 54). Spiral gradient endpoint assays employed 150-mm by 4-mm exponential-

gradient plates containing Mueller-Hinton II cation-adjusted agar and 0.5 to 100 $\mu\text{g/ml}$ of Myx, 0.0008 to 0.2 $\mu\text{g/ml}$ of Rif, or 0.2 to 40 $\mu\text{g/ml}$ of Rif. Plates were prepared using an Autoplate 4000 spiral plater (Spiral Biotech, Inc.). Cells were grown to early log phase, adjusted to 1×10^8 CFU/ml, and swabbed radially onto plates. Plates were incubated for 16 h at 37°C. For each culture, the streak length was measured using a clear plastic template (Spiral Biotech, Inc.), the test compound concentration at the streak endpoint was calculated using the program SGE (Spiral Biotech, Inc.), and the MIC was defined as the calculated test compound concentration at the streak endpoint.

MBCs. Minimal bactericidal concentrations (MBCs) were determined as follows. Cells (5×10^5 CFU/ml, diluted from log-phase cultures) were incubated for 16 h at 37°C in 100 μl of Mueller-Hinton II cation-adjusted broth containing amounts of test compound equivalent to 0 \times MIC, 0.5 \times MIC, 1 \times MIC, 2 \times MIC, or 4 \times MIC. Samples were diluted 1:1,000; aliquots were applied to Mueller-Hinton II cation-adjusted agar plates, plates were incubated for 16 h at 37°C, and colonies were counted. The MBC was defined as the lowest concentration of test compound that resulted in a $\geq 99.9\%$ reduction in colony count.

Spontaneous resistance rates. Resistance rates were determined using fluctuation assays (14, 24, 26, 57). Defined numbers of cells of *S. aureus* ATCC 12600 (1×10^9 CFU/plate) were plated on Mueller-Hinton II cation-adjusted agar containing amounts of test compound equivalent to 1 \times MIC, 2 \times MIC, 4 \times MIC, 8 \times MIC, or 16 \times MIC, and numbers of colonies were counted after 24 h at 37°C (at least five independent deter-

Received 21 May 2012 Returned for modification 24 June 2012

Accepted 16 September 2012

Published ahead of print 24 September 2012

Address correspondence to Richard H. Ebright, ebright@waksman.rutgers.edu.

A.S. and D.D. contributed equally to this article.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.01060-12

minations for each concentration of each test compound). Resistance rates and 95% confidence intervals were calculated using the Ma-Sandri-Sarkar maximum-likelihood estimator (MSS-MLE) (27, 44, 50) as implemented on the Fluctuation Analysis Calculator (FALCOR [http://www.keshavsinh.org/protocols/FALCOR.html]) (16). Sampling correction was performed as described previously (22, 51).

Sequencing of resistant mutants. Cells were lysed using 1 mg/ml lysozyme and 1 mg/ml lysostaphin (Sigma, Inc.). Genomic DNA was isolated using the Wizard Genomic DNA Purification Kit (Promega, Inc.) according to the procedures specified by the manufacturer, and genomic DNA was quantified by measurement of UV absorbance. The *rpoB* gene and the *rpoC* gene were PCR amplified in reaction mixtures containing 0.2 µg of genomic DNA, 0.4 µM forward and reverse oligonucleotide primers (5'-CGTTAAATAGATAAGTTAATTAAGAATAAATATAGAATCG-3' and 5'-TGGCTTAAAGTACTAAACTGAATCATC-3' for *rpoB*; 5'-GCCATTTTAAATAAATGCAAATCAATCAAATAGC-3' and 5'-CCTTTAAATATATTAACATTGAACAAGAGAATTCG-3' for *rpoC*), 5 U of *Taq* DNA polymerase (Genscript, Inc.), and 800 µM deoxynucleoside triphosphate (dNTP) mix (200 µM each dNTP; Agilent, Inc.). The PCR program consisted of an initial denaturation step of 5 min at 94°C, followed by 30 cycles of 30 s at 94°C, 45 s at 48°C, and 4 min at 72°C, with a final extension step of 10 min at 72°C. PCR products containing the *rpoB* gene (3.5 kb) or the *rpoC* gene (3.6 kb) were isolated by electrophoresis on 0.8% agarose, extracted from gel slices using a Gel/PCR DNA Fragments Extraction Kit (IBI Scientific, Inc.) according to the procedures specified by the manufacturer, and sequenced (Sanger sequencing; eight sequencing primers per gene).

Resistance fitness costs. Resistance fitness costs were quantified using pairwise-competition fitness assays, essentially as described previously (25, 55). Equal numbers of log-phase cells of an antibacterial-compound-resistant mutant and the isogenic wild-type parent ($\sim 1 \times 10^3$ CFU each) were mixed in 5 ml of Mueller-Hinton II cation-adjusted broth, and the mixed culture was incubated for 20 h (~ 20 to ~ 23 doubling times for the isogenic wild-type parent) at 37°C with shaking. At time zero and again at 20 h, the numbers of cells of the antibacterial-compound-resistant mutant and the isogenic wild-type parent were quantified by plating, in parallel, on Mueller-Hinton II cation-adjusted agar containing the antibacterial compound (6.25 µg/ml Myx or 0.012 µg/ml Rif) and on Mueller-Hinton II cation-adjusted agar without the antibacterial compound, followed by incubation for 20 to 40 h at 37°C and colony counting. Numbers of cells of the antibacterial-compound-resistant mutant were determined from the colony counts on plates containing the antibacterial compound. Numbers of cells of the isogenic wild-type parent were determined by subtracting the colony counts on plates containing the antibacterial compound from the colony counts on plates lacking the antibacterial compound.

The numbers of generations of the resistant mutant (G_{mut}) and of the wild-type parent (G_{wt}) were calculated according to Wichelhaus et al. (55):

$$G_{mut} = (\log B_{mut} - \log A_{mut}) / \log 2 \quad (1)$$

$$G_{wt} = (\log B_{wt} - \log A_{wt}) / \log 2 \quad (2)$$

where A_{mut} and A_{wt} are the numbers of CFU/ml for the mutant and wild-type, respectively, at time zero, and B_{wt} and B_{mut} are the numbers of CFU/ml for the mutant and wild-type, respectively, at 20 h.

The fitness cost (FC) was calculated according to Sander et al. (42):

$$FC = (1 - G_{mut}/G_{wt}) \times 100\% \quad (3)$$

Pairwise-competition fitness assays directly comparing Myx-resistant mutants and Rif-resistant mutants were performed in an analogous manner, mixing equal numbers of log-phase cells of a Myx-resistant mutant and an Rif-resistant mutant ($\sim 1 \times 10^3$ CFU each) and quantifying numbers of cells of the Myx-resistant mutant and the Rif-resistant mutant by plating on Mueller-Hinton II cation-adjusted agar containing 6.25 µg/ml

TABLE 1 Antibacterial activity of Myx

| <i>S. aureus</i> strain | Myx MIC (µg/ml) by assay method | | |
|-------------------------|---------------------------------|--------------------------|-----------------|
| | Broth microdilution | Spiral gradient endpoint | Myx MBC (µg/ml) |
| ATCC 12600 MSSA | 1.56 | 0.86 | 3.13 |
| ATCC 13709 MSSA | 1.56 | 0.86 | 6.25 |
| ATCC 29213 MSSA | 1.56 | 0.86 | 6.25 |
| BAA-1707 MRSA (MW2) | 0.78 | 0.80 | 3.13 |
| BAA-1717 MRSA (USA300) | 0.78 | 0.80 | 3.13 |

Myx and on Mueller-Hinton II cation-adjusted agar containing 0.012 µg/ml Rif, respectively.

RESULTS

Antibacterial activity of Myx in *S. aureus* MSSA and *S. aureus* MRSA. To assess antibacterial activity, we performed MIC assays and minimal bactericidal concentration (MBC) assays. Results are presented in Table 1. The results indicate, consistent with previous reports (19, 20, 31, 33, 49), that Myx exhibits potent antibacterial activity against both methicillin-sensitive *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA) (MICs of 0.78 to 1.56 µg/ml). Results of spiral gradient endpoint MIC assays are identical, within one 2-fold serial dilution interval, to results of broth microdilution MIC assays. The results further indicate that Myx is bactericidal against both MSSA and MRSA at concentrations approximately 2× to 3× MIC (MBC of 3.13 to 6.25 µg/ml).

Myx resistance in *S. aureus*: resistance rate. To assess the spontaneous resistance rate for Myx, we performed fluctuation assays (14, 24, 26, 57), plating defined numbers of cells ($\sim 10^9$ CFU/plate) of *S. aureus* ATCC 12600 on agar containing 1×, 2×, 4×, 8×, or 16× MIC of Myx, counting numbers of resistant colonies after 24 h of incubation at 37°C, and calculating resistance rates using the MSS-MLE method (16, 22, 27, 44, 50, 51). For comparison, we assayed the resistance rate for Rif under the identical experimental conditions. The results are presented in Table 2. The observed resistance rates for Myx at 1×, 2×, 4×, 8×, and 16× MIC were 7×10^{-8} , 7×10^{-8} , 6×10^{-8} , 4×10^{-8} , and 4×10^{-8} per generation, respectively. The observed resistance rates for Rif at 1×, 2×, 4×, 8× and 16× MIC were 10×10^{-8} , 6×10^{-8} , 6×10^{-8} , 3×10^{-8} , and 3×10^{-8} , respectively, per generation, consistent with previously reported values for Rif (30, 34). Within experimental error, the observed resistance rates for Myx and Rif were identical. We conclude, consistent with previous work (31), that the resistance rates for Myx and Rif are equal or comparable.

Myx resistance in *S. aureus*: resistance spectrum. To define the resistance spectrum for Myx, we isolated and sequenced the *rpoB* and *rpoC* genes, encoding the RNAP β and β' subunits, from each of 17 independent spontaneous Myx-resistant mutants identified in the experiments described in the preceding section. For comparison, to define the resistance spectrum for Rif under identical experimental conditions, we isolated and sequenced the *rpoB* gene from each of 24 independent spontaneous Rif-resistant mutants identified in the experiments described in the preceding section.

The results for Myx resistance are presented in Table 3 and Fig. 1B. All Myx-resistant mutants were found to contain mutations in

TABLE 2 Resistance rates for Myx and Rif

| Inhibitor | Concn (\times MIC) | Resistance rate per generation (95% confidence interval) |
|-----------|-----------------------|--|
| Myx | 1 | $7 (4-11) \times 10^{-8}$ |
| | 2 | $7 (4-10) \times 10^{-8}$ |
| | 4 | $6 (3-8) \times 10^{-8}$ |
| | 8 | $4 (2-7) \times 10^{-8}$ |
| | 16 | $4 (2-7) \times 10^{-8}$ |
| Rif | 1 | $10 (6-14) \times 10^{-8}$ |
| | 2 | $6 (3-9) \times 10^{-8}$ |
| | 4 | $6 (5-8) \times 10^{-8}$ |
| | 8 | $3 (1-6) \times 10^{-8}$ |
| | 16 | $3 (1-6) \times 10^{-8}$ |

rpoB or *rpoC*, confirming that RNAP is the primary or exclusive functional cellular target of Myx in *S. aureus*. All 17 Myx-resistant mutants were single-substitution mutants. Six substitutions conferring Myx resistance were identified in the RNAP β subunit [V1080(1275)I, V1080(1275)L, E1084(1279)K, D1101(1296)E, S1127(1322)L, and S1127(1322)P], and five substitutions conferring Myx resistance were identified in the RNAP β' subunit [K334(345)N, T925(917)K, T925(917)R, G1172(1354)C, and G1172(1354)D] (residues numbered as in *S. aureus* RNAP and, in parentheses, as in *Escherichia coli* RNAP). Four of the substitutions previously were reported as Myx-resistant substitutions in *E. coli* [E1084(1279)K and S1127(1322)P in the RNAP β subunit; K334(345)N and G1172(1354)C in the RNAP β' subunit] (32), and three of the substitutions previously were reported as Myx-resistant substitutions in *S. aureus* [S1127(1322)L in the RNAP β subunit; K334(345)N and T925(917)R in the RNAP β' subunit] (31). All sites of substitutions conferring Myx resistance mapped to the binding site on RNAP for Myx, located in the SW1/SW2 subregion of the RNAP switch region (Fig. 1A and B). None overlapped the binding site on RNAP for Rif (Fig. 1C) or the resistance spectrum on RNAP for Rif (Fig. 1D). Resistance and cross-resistance levels were quantified using spiral gradient endpoint assays (38, 45, 54). Six substitutions resulted in 20-fold resistance to Myx, and five substitutions resulted in >100-fold resistance to Myx (Table 3). (Compound availability precluded assays at >100 \times MIC.) The median resistance level was 20-fold. Consistent with the absence of overlap with the binding site for Rif, no Myx-resistant substitution conferred cross-resistance to Rif (Table 3).

The results for Rif are presented in Table 4 and Fig. 1D. All Rif-resistant mutants contained mutations in *rpoB*, consistent with previous reports for Rif resistance in *S. aureus* and in other bacterial species (2, 4, 7, 10–13, 15, 17, 21, 29, 35–37, 40, 41, 43, 46–48, 52, 53, 55, 56). All identified Rif-resistant mutants were single-substitution mutants. Nine substitutions conferring Rif resistance were identified in the RNAP β subunit [S464(509)P, D471(516)G, D471(516)Y, A477(522)D, A477(522)V, H481(526)N, H481(526)R, H481(526)Y, and S486(531)L]. One Rif-resistant substitution resulted in 60-fold resistance, two resulted in 100-fold resistance, one resulted in 300-fold resistance, and all others resulted in \geq 2,000-fold resistance (Table 4). The median resistance level was 2,000-fold. Consistent with the absence of overlap with the binding site for Myx (Fig. 1), no Rif-resistant substitution conferred cross-resistance to Myx (Table 4).

TABLE 3 Sequences, resistance levels, and fitness costs of Myx-resistant mutants

| RNAP subunit and amino acid substitution ^a | No. of independent isolates | MIC/MIC _{wt} ^b | | Fitness cost (% per generation [\pm SEM]) |
|---|-----------------------------|------------------------------------|-----|--|
| | | Myx | Rif | |
| β Subunit (<i>rpoB</i>) | | | | |
| 1080 (1275) Val \rightarrow Ile | 1 | 20 | 1 | 8 (\pm 2) |
| 1080 (1275) Val \rightarrow Leu | 1 | 20 | 1 | 12 (\pm 3) |
| 1084 (1279) Glu \rightarrow Lys | 1 | >100 | 1 | 8 (\pm 4) |
| 1101 (1296) Asp \rightarrow Glu | 1 | 20 | 1 | 15 (\pm 1) |
| 1127 (1322) Ser \rightarrow Leu | 3 | >100 | 1 | 10 (\pm 3) |
| 1127 (1322) Ser \rightarrow Pro | 2 | >100 | 1 | 4 (\pm 2) |
| β' Subunit (<i>rpoC</i>) | | | | |
| 334 (345) Lys \rightarrow Asn | 3 | >100 | 1 | 6 (\pm 2) |
| 925 (917) Thr \rightarrow Lys | 1 | 20 | 1 | 7 (\pm 1) |
| 925 (917) Thr \rightarrow Arg | 1 | >100 | 1 | 5 (\pm 2) |
| 1172 (1354) Gly \rightarrow Cys | 1 | 20 | 1 | 13 (\pm 1) |
| 1172 (1354) Gly \rightarrow Asp | 2 | 20 | 1 | 14 (\pm 1) |

^a Residues are numbered as in *S. aureus* RNAP and, in parentheses, as in *E. coli* RNAP.

^b MICs were determined using spiral gradient endpoint assays. The MIC of the wild-type parent (MIC_{wt}) is 0.86 μ g/ml for Myx and 0.008 μ g/ml for Rif.

We conclude that the Myx resistance spectrum in *S. aureus* comprises substitutions of residues of the Myx binding site located in the SW1/SW2 subregion of the RNAP switch region and that the Myx resistance spectrum does not overlap the Rif resistance spectrum (Tables 3 and 4; Fig. 1). We conclude further that Myx-resistant mutants exhibit generally lower resistance levels than Rif-resistant mutants (with at least 6 of the 11 Myx-resistant mutants exhibiting resistance levels lower than any of the 9 Rif-resistant mutants and with a multiple-order-of-magnitude difference in median resistance levels: i.e., 20-fold versus 2,000-fold).

Myx resistance in *S. aureus*: resistance fitness costs. To assess the fitness cost of Myx-resistant mutants, we performed pairwise-competition fitness assays, essentially as described by Lenski and by Wichelhaus et al. (25, 55). For each identified Myx-resistant mutant, we mixed equal numbers of cells of the Myx-resistant mutant and the isogenic wild-type parent (1×10^3 CFU of each), incubated the mixed culture for 20 h at 37°C (20 to 23 doubling times for the wild-type parent), quantified Myx-resistant and wild-type cells by plating cultures in parallel to medium with Myx and without Myx, and calculated the fitness cost per generation (see Materials and Methods). For comparison, we assessed the fitness cost, under identical experimental conditions, for each identified Rif-resistant mutant.

The results for Myx-resistant mutants are presented in Table 3. All Myx-resistant mutants exhibited nonzero, >0% per generation, fitness costs. The lowest and highest fitness costs were 4% per generation and 15% per generation, respectively. The mean and median fitness costs were 9% per generation and 8% per generation, respectively. Growth rates of three mutants with substitutions of the RNAP switch region previously have been assessed (28), but the data in the present study provide the first quantitative measurements of fitness costs of any mutant with substitutions of the RNAP switch region.

The results for Rif are presented in Table 4, column 5. Three Rif-resistant mutants have fitness costs of zero or less than zero: D471(516)G, D471(516)Y, and H481(526)N (Table 4, boldface).




FIG 1 Locations of binding sites and sites of resistance substitutions for Myx and Rif in the structure of bacterial RNAP. (A) Binding site for Myx (Myx shown in red) (32). (B) Resistance spectrum for Myx in *S. aureus* (sites of Myx-resistant substitutions identified in this study shown in red) (Table 3). (C) Binding site for Rif (Rif shown in blue) (6). (D) Resistance spectrum for Rif in *S. aureus* (sites of Rif-resistant substitutions identified in this study shown in blue) (Table 4). Atomic coordinates for RNAP and Myx are from a crystal structure of the *Thermus thermophilus* RNAP-Myx complex (32) (Protein Data Bank [PDB] accession code 3DXJ); σ subunit and β' subunit nonconserved regions omitted for clarity). Atomic coordinates for Rif are from the crystal structure of the *Thermus aquaticus* RNAP-Rif complex (6) (PDB accession code 1I6V). The RNAP active-center Mg^{2+} is shown as a violet sphere for reference.

TABLE 4 Sequences, resistance levels, and fitness costs of Rif-resistant mutants

| RNAP β subunit (<i>rpoB</i>) mutation ^a | No. of independent isolates | MIC/MIC _{wt} ^b | | Fitness cost (% per generation [\pm SEM]) ^c |
|--|-----------------------------|------------------------------------|-----|---|
| | | Rif | Myx | |
| 464 (509) Ser \rightarrow Pro | 1 | 2,000 | 1 | 13 (± 2) |
| 471 (516) Asp \rightarrow Gly | 7 | 60 | 1 | 0 (-5 ± 7) |
| 471 (516) Asp \rightarrow Tyr | 2 | 100 | 1 | 0 (± 3) |
| 477 (522) Ala \rightarrow Asp | 3 | >5,000 | 1 | 9 (± 6) |
| 477 (522) Ala \rightarrow Val | 1 | 100 | 1 | 10 (± 5) |
| 481 (526) His \rightarrow Asn | 1 | 300 | 1 | 0 (-1 ± 2) |
| 481 (526) His \rightarrow Arg | 1 | >5,000 | 1 | 6 (± 4) |
| 481 (526) His \rightarrow Tyr | 6 | >5,000 | 1 | 14 (± 1) |
| 486 (531) Ser \rightarrow Leu | 2 | >5,000 | 1 | 13 (± 6) |

^a Residues are numbered as in *S. aureus* RNAP and, in parentheses, as in *E. coli* RNAP.

^b MICs were determined using spiral gradient endpoint assays. The Myx MIC for the wild type (MIC_{wt}) is 0.86 μ g/ml, and the Rif MIC_{wt} is 0.008 μ g/ml.

^c Observed fitness costs of the Rif-resistant mutants of ≤ 0 are shown as 0 and are highlighted in boldface. Observed fitness costs of < 0 are shown in parentheses \pm standard errors of the means.

The observed fitness costs for Rif-resistant mutants in *S. aureus* are in agreement with previously reported data (55). The conclusion that a subset of Rif-resistant mutants exhibit fitness costs of zero or less than zero is in agreement with previous work for multiple bacterial species, including *S. aureus* (55), *Enterococcus faecium* (11), *Mycobacterium tuberculosis* (4, 15), and *E. coli* (41).

To assess the significance of the observed difference in fitness costs of Myx-resistant mutants and Rif-resistant mutants, we performed direct pairwise-competition fitness assays between the two lowest-fitness-cost Myx-resistant mutants [β S1127(1322)P and β' T925(917)R; fitness costs of 4% per generation and 5% per generation, respectively] and a zero-fitness cost Rif-resistant mutant [β H481(526)N]. The results are presented in Table 5. The results confirm that the two lowest-fitness-cost Myx-resistant mutants are significantly less fit than the zero-fitness-cost Rif-resistant mutant. The observed relative fitness costs are equal within error to the predicted relative fitness costs calculated as the difference between the fitness costs of the Myx-resistant mutants

TABLE 5 Direct determination of relative fitness costs of lowest-fitness-cost Myx-resistant mutants and zero-fitness-cost Rif-resistant mutant

| Myx-resistant mutant (RNAP subunit and mutation) ^a | Rif-resistant mutant (RNAP subunit and mutation) ^a | Relative fitness cost of Myx resistance vs Rif-resistance (% per generation [\pm SEM]) | |
|---|---|---|-----------------------------|
| | | Predicted value ^b | Observed value ^c |
| β 1127 (1322) Ser \rightarrow Pro | β 481 (526) His \rightarrow Asn | 5 (\pm 4) | 6 (\pm 2) |
| β' 925 (917) Thr \rightarrow Lys | β 481 (526) His \rightarrow Asn | 8 (\pm 3) | 8 (\pm 1) |

^a Residues are numbered as in *S. aureus* RNAP and, in parentheses, as in *E. coli* RNAP.

^b Predicted relative fitness costs are calculated as the fitness cost of the Myx-resistant mutant (Table 3) minus the fitness cost of the Rif-resistant mutant (Table 4).

^c Observed relative fitness costs are from pairwise-competition fitness assays directly comparing the Myx-resistant mutant and the Rif-resistant mutant.

and the Rif-resistant mutant. We conclude that all Myx-resistant mutants—but not all Rif-resistant mutants—have significant nonzero fitness costs.

To assess whether fitness costs of Myx-resistant mutants are stable or whether fitness costs decrease due to the emergence of compensatory mutations, we measured fitness costs of representative Myx-resistant mutants [β V1080(1275)Ile and β' K334(345)N; fitness costs of 8% per generation and 6% per generation, respectively] after 0, 1, and 2 serial passages. Fitness costs did not change after up to 2 serial passages (Table 6).

DISCUSSION

Our results show that Myx has bactericidal activity in *S. aureus* (Table 1) and define the resistance properties of Myx in *S. aureus* (Tables 2 to 4; Fig. 1). Our results indicate that the spontaneous resistance rate for Myx is equal or comparable to that for Rif (Table 2), that the resistance spectrum for Myx does not overlap the resistance spectrum for Rif (Tables 3 and 4; Fig. 1B and D), that the resistance levels of Myx-resistant mutants generally are lower than those of Rif-resistant mutants (Tables 3 and 4), and that the resistance fitness costs of all Myx-resistant mutants—but not all Rif-resistant mutants—are greater than zero (Tables 3 and 4).

The finding that the resistance levels of Myx-resistant mutants generally are lower than those of Rif-resistant mutants, together with the finding that fitness costs of all Myx-resistant mutants—but not all Rif-resistant mutants—are greater than zero, supports the viability of Myx as a lead compound for antibacterial drug development.

The finding that all Myx-resistant mutants, but not all Rif-resistant mutants, have significant nonzero fitness costs is particularly noteworthy. Previous work has established a strong correlation between the fitness cost of antibacterial-agent-resistant mutants and the clinical prevalence of antibacterial-agent-resistant mutants (1, 4, 5, 9, 10, 15, 35, 42, 55). For Rif, this correlation is especially strong (4, 10, 15, 35, 55). Rif-resistant substitutions

that have zero or subzero fitness costs are highly significantly over-represented in Rif-resistant clinical isolates across multiple bacterial species (4, 10, 15, 35, 55). The three Rif-resistant substitutions that we have found to have zero fitness costs in *S. aureus* [D(516)G, D(516)Y, and H(526)N] account for more than 50% of sequenced Rif-resistant clinical isolates of *S. aureus* (2, 17, 29, 35, 46, 52, 53, 56) and more than 50% of sequenced Rif-resistant clinical isolates of *Streptococcus pneumoniae* (7, 12, 13, 37). The three Rif-resistant substitutions that we have found to have zero fitness costs in *S. aureus* [D(516)G, D(516)Y, and H(526)N], together with another substitution found to have zero fitness cost in *M. tuberculosis* [S(531)L] (4, 15), account for more than 35% of sequenced Rif-resistant clinical isolates of *M. tuberculosis* (40, 43).

The difference in fitness costs of Myx resistance and Rif resistance presumably relates to the fact that the binding site on RNAP for Myx (the RNAP switch region SW1/SW2 subregion) performs critical functions in opening and closing the RNAP active-center cleft and in DNA binding (3, 18, 32, 39, 49), whereas the binding site on RNAP for Rif performs no critical functions (18). Accordingly, substitutions in the SW1/SW2 subregion of the RNAP switch region presumably are more likely to impair RNAP function and thereby to impair viability. Since the nonzero fitness costs are likely to be a property of the switch region SW1/SW2 subregion, it is likely that nonzero fitness costs will be observed not only with Myx but also with other RNAP inhibitors that function through the switch region SW1/SW2 subregion, including coralopyronin and ripostatin (32, 49).

ACKNOWLEDGMENTS

This work was supported by NIH grants AI072766 and AI90837, a Global Alliance for TB Drug Development contract, and a Howard Hughes Medical Institute Investigatorship to R.H.E.

REFERENCES

- Andersson DI. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? *Curr. Opin. Microbiol.* 9:461–465.
- Aubry-Damon H, Soussy CJ, Courvalin P. 1998. Characterization of mutations in the *rpoB* gene that confer rifampin resistance in *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 42:2590–2594.
- Belogurov GA, et al. 2009. Transcription inactivation through local refolding of the RNA polymerase structure. *Nature* 457:332–335.
- Billington OJ, McHugh TD, Gillespie SH. 1999. Physiological cost of rifampin resistance induced in vitro in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* 43:1866–1869.
- Böttger EC, Springer B, Pletschette M, Sander P. 1998. Fitness of antibiotic-resistant microorganisms and compensatory mutations. *Nat. Med.* 4:1343–1344.
- Campbell EA, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell* 104:901–912.
- Chen JY, et al. 2004. Mutations of the *rpoB* gene in rifampicin-resistant *Streptococcus pneumoniae* in Taiwan. *J. Antimicrob. Chemother.* 53:375–378.

TABLE 6 Fitness costs of Myx-resistant mutants after 0, 1, and 2 serial passages

| RNAP subunit and mutation ^a | No. of serial passages | Fitness cost (% per generation [\pm SEM]) |
|---|------------------------|--|
| β 1080 (1275) Val \rightarrow Ile | 0 | 8 (\pm 2) |
| | 1 | 9 (\pm 1) |
| | 2 | 9 (\pm 1) |
| β' 334 (345) Lys \rightarrow Asn | 0 | 6 (\pm 2) |
| | 1 | 6 (\pm 1) |
| | 2 | 8 (\pm 1) |

^a Residues are numbered as in *S. aureus* RNAP and, in parentheses, as in *E. coli* RNAP.

8. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A8, 8th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Cohen T, Murray M. 2004. Modeling epidemics of multidrug-resistant *M. tuberculosis* of heterogeneous fitness. *Nat. Med.* 10:1117–1121.
10. Comas I, et al. 2012. Whole-genome sequencing of rifampicin-resistant *Mycobacterium tuberculosis* strains identifies compensatory mutations in RNA polymerase genes. *Nat. Genet.* 44:106–110.
11. Enne VI, Delsol AA, Roe JM, Bennett PM. 2004. Rifampicin resistance and its fitness cost in *Enterococcus faecium*. *J. Antimicrob. Chemother.* 53:203–207.
12. Enright M, Zawadzki P, Pickerill P, Dowson CG. 1998. Molecular evolution of rifampicin resistance in *Streptococcus pneumoniae*. *Microb. Drug Resist.* 4:65–70.
13. Ferrándiz MJ, et al. 2005. New mutations and horizontal transfer of *rpoB* among rifampin-resistant *Streptococcus pneumoniae* from four Spanish hospitals. *Antimicrob. Agents Chemother.* 49:2237–2245.
14. Foster PL. 2006. Methods for determining spontaneous mutation rates. *Methods Enzymol.* 409:195–213.
15. Gagneux S, et al. 2006. The competitive cost of antibiotic resistance in *Mycobacterium tuberculosis*. *Science* 312:1944–1946.
16. Hall BM, Ma CX, Liang P, Singh KK. 2009. Fluctuation analysis Calculator: a web tool for the determination of mutation rate using Luria-Delbrück fluctuation analysis. *Bioinformatics* 25:1564–1565.
17. Hellmark B, Söderquist B, Unemo M. 2009. Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the *rpoB* gene. *Eur. J. Clin. Microbiol. Infect. Dis.* 28:183–190.
18. Ho MX, Hudson BP, Das K, Arnold E, Ebright RH. 2009. Structures of RNA polymerase-antibiotic complexes. *Curr. Opin. Struct. Biol.* 19:715–723.
19. Hu T, et al. 1998. Total synthesis and preliminary antibacterial evaluation of the RNA polymerase inhibitors (\pm)-myxopyronin A and B. *J. Org. Chem.* 63:2401–2406.
20. Irschik H, Gerth K, Höfle G, Kohl W, Reichenbach H. 1983. The myxopyronins, new inhibitors of bacterial RNA synthesis from *Myxococcus fulvus* (Myxobacterales). *J. Antibiot. (Tokyo)* 36:1651–1658.
21. Jin DJ, Gross CA. 1988. Mapping and sequencing of mutations in the *Escherichia coli rpoB* gene that lead to rifampicin resistance. *J. Mol. Biol.* 202:45–58.
22. Jones ME. 1993. Accounting for plating efficiency when estimating spontaneous mutation rates. *Mutat. Res.* 292:187–189.
23. Kohl W, Irschik H, Reichenbach H, Höfle G. 1983. Antibiotika aus Gleitenden Bakterien, XVII. Myxopyronin A und B—zwei neue Antibiotika aus *Myxococcus fulvus* Stamm Mx f50. *Liebigs Ann. Chemie* 1983: 1656–1667.
24. Lea D, Coulson C. 1949. The distribution of the numbers of mutants in bacterial populations. *J. Genet.* 49:264–285.
25. Lenski RE. 1988. Experimental studies of pleiotropy and epistasis in *Escherichia coli*. I. Variation in competitive fitness among mutants resistant to virus T4. *Evolution* 42:425–432.
26. Luria SE, Delbrück M. 1943. Mutations of bacteria from virus sensitivity to virus resistance. *Genetics* 28:491–511.
27. Ma WT, Sandri GV, Sarkar S. 1992. Analysis of the Luria-Delbrück distribution using discrete convolution powers. *J. Appl. Probab.* 29:255–267.
28. Mariner K, et al. 2011. Activity of and development of resistance to coralopyronin A, an inhibitor of RNA polymerase. *Antimicrob. Agents Chemother.* 55:2413–2416.
29. Mick V, et al. 2010. Molecular characterization of resistance to rifampicin in an emerging hospital-associated methicillin-resistant *Staphylococcus aureus* clone ST228, Spain. *BMC Microbiol.* 10:68. doi:10.1186/1471-2180-10-68.
30. Moorman DR, Mandell GL. 1981. Characteristics of rifampin-resistant variants obtained from clinical isolates of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 20:709–713.
31. Moy TI, et al. 2011. Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against *Staphylococcus aureus*. *FEMS Microbiol. Lett.* 319:176–179.
32. Mukhopadhyay J, et al. 2008. The RNA polymerase “switch region” is a target for inhibitors. *Cell* 135:295–307.
33. O'Neill A, et al. 2000. RNA polymerase inhibitors with activity against rifampin-resistant mutants of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 44:3163–3166.
34. O'Neill AJ, Cove JH, Chopra I. 2001. Mutation frequencies for resistance to fusidic acid and rifampicin in *Staphylococcus aureus*. *J. Antimicrob. Chemother.* 47:647–650.
35. O'Neill AJ, Huovinen T, Fishwick CW, Chopra I. 2006. Molecular genetic and structural modeling studies of *Staphylococcus aureus* RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. *Antimicrob. Agents Chemother.* 50:298–309.
36. Ovchinnikov YA, et al. 1983. RNA polymerase rifampicin resistance mutations in *Escherichia coli*: sequence changes and dominance. *Mol. Gen. Genet.* 190:344–348.
37. Padayachee T, Klugman KP. 1999. Molecular basis of rifampin resistance in *Streptococcus pneumoniae*. *Antimicrob. Agents Chemother.* 43:2361–2365.
38. Paton JH, Holt AH, Bywater MJ. 1990. Measurement of MICs of antibacterial agents by spiral gradient endpoint compared with conventional dilution method. *Int. J. Exp. Clin. Chemother.* 3:31–38.
39. Pupov D, et al. 2010. Multiple roles of the RNA polymerase β' SW2 region in transcription initiation, promoter escape, and RNA elongation. *Nucleic Acids Res.* 38:5784–5796.
40. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in *Mycobacterium tuberculosis*: 1998 update. *Tuber. Lung Dis.* 79:3–29.
41. Reynolds MG. 2000. Compensatory evolution in rifampin-resistant *Escherichia coli*. *Genetics* 156:1471–1481.
42. Sander P, et al. 2002. Fitness cost of chromosomal drug resistance-conferring mutations. *Antimicrob. Agents Chemother.* 46:1204–1211.
43. Sandgren A, et al. 2009. Tuberculosis drug resistance mutation database. *PLoS Med.* 6:e2. doi:10.1371/journal.pmed.1000002.
44. Sarkar S, Ma WT, Sandri GV. 1992. On fluctuation analysis: a new, simple and efficient method for computing the expected number of mutants. *Genetica* 85:173–179.
45. Schalkowsky S. 1994. Measures of susceptibility from a spiral gradient of drug concentrations. *Adv. Exp. Med. Biol.* 349:107–120.
46. Sekiguchi J, et al. 2006. Emergence of rifampicin resistance in methicillin-resistant *Staphylococcus aureus* in tuberculosis wards. *J. Infect. Chemother.* 12:47–50.
47. Severinov K, Soushko M, Goldfarb A, Nikiforov V. 1993. Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the beta subunit of *Escherichia coli* RNA polymerase. *J. Biol. Chem.* 268:14820–14825.
48. Severinov K, Soushko M, Goldfarb A, Nikiforov V. 1994. RifR mutations in the beginning of the *Escherichia coli rpoB* gene. *Mol. Gen. Genet.* 244:120–126.
49. Srivastava A, et al. 2011. New target for inhibition of bacterial RNA polymerase: “switch region.” *Curr. Opin. Microbiol.* 14:532–543.
50. Stewart FM. 1994. Fluctuation tests: how reliable are the estimates of mutation rates? *Genetics* 137:1139–1146.
51. Stewart FM, Gordon DM, Levin BR. 1990. Fluctuation analysis: the probability distribution of the number of mutants under different conditions. *Genetics* 124:175–185.
52. van Rensburg MJ, Whitelaw A, Elisha B. 2012. Genetic basis of rifampicin resistance in methicillin-resistant *Staphylococcus aureus* suggests clonal expansion in hospitals in Cape Town, South Africa. *BMC Microbiol.* 12:46. doi:10.1186/1471-2180-12-46.
53. Villar M, et al. 2011. Epidemiological and molecular aspects of rifampicin-resistant *Staphylococcus aureus* isolated from wounds, blood and respiratory samples. *J. Antimicrob. Chemother.* 66:997–1000.
54. Wallace AS, Corkill JE. 1989. Application of the spiral plating method to study antimicrobial action. *J. Microbiol. Methods* 10:303–310.
55. Wichelhaus TA, et al. 2002. Biological cost of rifampin resistance from the perspective of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 46:3381–3385.
56. Wichelhaus TA, Schäfer V, Brade V, Böddinghaus B. 1999. Molecular characterization of *rpoB* mutations conferring cross-resistance to rifamycins on methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 43:2813–2816.
57. Young K. 2006. In vitro antibacterial resistance selection and quantitation. *Curr. Protoc. Pharmacol.*, chapter 13, unit 13A.6. doi:10.1002/0471141755.ph13a06s34.